Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Honey available in New Zeland can contain the toxins tutin and hyenanchin. Tutin is produced by several plants native to New Zealand. Bees collect honeydew contaminated with tutin and hyenanchin for honey production.
Honey contaminated with high levels of tutin has caused cases of poisoning in New Zealand since the 1800s, with the most recent outbreak in 2008.
The study aims to find out how tutin and hyenanchin are absorbed and processed by the body. This information will help the FSANZ give guidance on acceptable levels of tutin and hyenanchin in honey.
About 6 healthy men will each take a single dose of honey containing known concentrations of tutin and hyenanchin.
This dose level is similar to what someone who eats a lot of honey would have, if the honey contained the maximum level of tutin allowed under the Food Standards Code.
Blood tests to measure tutin and hyenanchin levels will be taken at certain times after dosing, and any side effects will be recorded.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Honey substance | Other | Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin. Subjects to receive single dose of test material such that each subject receives 1.8 mcg/kg body weight of tutin. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Honey substance | Other | Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics of tutin and hyenanchin (Tmax) | Time to maximum plasma concentration (Tmax) | Pre-dose through to 24 hours post dose. May be modified according to sentinal PK results. |
| Pharmacokinetics of tutin and hyenanchin (AUC) | Area under the plasma concentration versus time curve (AUC) | Pre-dose through to 24 hours post dose |
| Pharmacokinetics of tutin and hyenanchin (Cmax) | Peak Plasma Concentration (Cmax) | Pre-dose through to 24 hours post dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chris Wynne, MBChB | Christchurch Clinical Studies Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Christchurch Clinical Studies Trust | Christchurch | Canterbury | 8011 | New Zealand |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided